Coya Therapeutics Q3 Revenue Down 12% YoY, FDA Accepts ALS Treatment IND.

Wednesday, Nov 12, 2025 8:09 am ET1min read
COYA--

• Coya Therapeutics reports Q3 financial results • FDA accepts IND application for COYA 302 for ALS treatment • Received $4.2 million from Dr. Reddy's Laboratories • Published study linking inflammation to Parkinson's progression • Announced FDA acceptance of IND application for COYA 302 • Coya Therapeutics focuses on developing biologics for neurodegenerative disorders • Company provides corporate update and announces financial results • Coya Therapeutics is a clinical-stage biotechnology company based in Houston, TX

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet